ArticleJournal of thoracic disease2026
Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative atezolizumab is approved as adjuvant therapy for programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in Japan, based on the phase III IMpower010 trial. However, real-world data on this therapeutic approach remains limited. This study aimed to evaluate the real-world effectiveness and safety of adjuvant atezolizumab in patients with pathological stage II-III NSCLC. Methods: This single-institution retrospective cohort study included patients with completely resected pathological stage IIA-IIIB [Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system version 8] NSCLC who received at least one cycle of adjuvant atezolizumab after platinum-based chemotherapy between January 2021 and December 2024. Clinical characteristics, treatment completion, disease-free survival (DFS), overall survival (OS), and adverse events (AEs) were evaluated. Survival outcomes were estimated using the Kaplan-Meier method. Results: Among 646 patients who underwent curative-intent surgery, 25 met the eligibility criteria and received adjuvant atezolizumab. PD-L1 expression assessed using the 22C3 assay was <1% in 1 patient, 1-49% in 11, and ≥50% in 13; notably, the patient with PD-L1 <1% on 22C3 testing was found to be positive on SP263 testing. Median follow-up was 27.4 months. Median DFS was not reached; the 2-year DFS rate was 63.8%, with comparable outcomes between PD-L1 subgroups (PD-L1 1-49%: 72.9% Conclusions: In this real-world cohort, adjuvant atezolizumab demonstrated favorable tolerability and clinically meaningful DFS across PD-L1 expression subgroups, including patients with PD-L1 1-49%. These findings are descriptive in nature and should be interpreted with caution, nevertheless, they provide real-world evidence supporting the potential clinical utility of adjuvant atezolizumab in appropriately selected patients with resected stage II-III NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.